Immune cells with specific functions and abilities are vital to cancer treatment prevention.
Although there have been many accomplishments made in the areas of immunotherapy and
immunobiology of myeloma, there are still many obstacles in the way of conceptualizing
the interrelationships between immune cells and tumor cells. To provide better understanding
of these concepts and to move toward improved therapies for myeloma, cell-based therapeutic
approaches should be developed.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Immunoregulatory mechanisms in multiple myeloma.Hematol Oncol Clin North Am. 1997; 11: 51-69
- Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion.Immunity. 2000; 13: 829-840
- Dendritic cells and the control of immunity.Nature. 1998; 392: 245-252
- Genetic instabilities in human cancers.Nature. 1998; 396: 643-649
- Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.Clin Cancer Res. 2004; 10: 770-776
- The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.Immunity. 1999; 10: 673-679
- The microenvironment of the tumour-host interface.Nature. 2001; 411: 375-379
- Clinical trial designs for the early clinical development of therapeutic cancer vaccines.J Clin Oncol. 2001; 19: 1848-1854
- Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.J Immunol. 2003; 170: 5391-5397
- CD4 + T cells are required for secondary expansion and memory in CD8 + T lymphocytes.Nature. 2003; 421: 852-856
- Defective CD8 T cell memory following acute infection without CD4 T cell help.Science. 2003; 300: 339-342
- Requirement for CD4 T cell help in generating functional CD8 T cell memory.Science. 2003; 300: 337-339
- Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.Nat Immunol. 2004; 5: 1143-1148
- The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery.Immunity. 1999; 11: 173-181
- Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4 + T cell homeostatic expansion.Nat Immunol. 2004; 5: 426-434
- Control of regulatory T cell development by the transcription factor Foxp3.Science. 2003; 299: 1057-1061
- Early events in the thymus affect the balance of effector and regulatory T cells.Nature. 2006; 444: 1073-1077
- Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.Nature. 2007; 445: 936-940
- Foxp3-dependent program of regulatory T-cell differentiation.Nature. 2007; 445: 771-775
- Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression.Nature. 2007; 445: 766-770
- Foxp3 occupancy and regulation of key target genes during T-cell stimulation.Nature. 2007; 445: 931-935
- FOXP3 controls regulatory T cell function through cooperation with NFAT.Cell. 2006; 126: 375-387
- The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells.Cell. 2006; 126: 1121-1133
- Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.Nat Immunol. 2007; 8: 639-646
- Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.Nat Immunol. 2007; 8: 942-949
- Development, cytokine profile and function of human interleukin 17-producing helper T cells.Nat Immunol. 2007; 8: 950-959
- Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.Nature. 2001; 413: 165-171
- Host immune system gene targeting by a viral miRNA.Science. 2007; 317: 376-381
- Regulatory T cells: key controllers of immunologic self-tolerance.Cell. 2000; 101: 455-458
- Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.Science. 2007; 317: 256-260
- Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.Nature. 2007; 446: 685-689
- FOXP3: of mice and men.Annu Rev Immunol. 2006; 24: 209-226
- TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.Immunity. 2006; 24: 179-189
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature. 2006; 441: 235-238
- Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.Immunity. 2007; 26: 371-381
- Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex.Blood. 1991; 78: 1770-1780
- Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.Blood. 2001; 98: 2992-2998
- Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.Blood. 2003; 101: 4005-4012
- Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.Br J Haematol. 2001; 113: 1051-1059
- Viral antigen-specific CD8 + T-cell responses are impaired in multiple myeloma.Br J Haematol. 2003; 121: 842-848
- Recurrent pneumonia in multiple myeloma and some observations on immunologic response.Ann Intern Med. 1954; 41: 1152-1163
- Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.Br J Cancer. 2000; 82: 1261-1265
- Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.Blood. 1999; 93: 1487-1495
- Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein.Exp Hematol. 2001; 29: 85-92
- Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.Blood. 2002; 100: 230-237
- Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.Blood. 2006; 108: 4071-4077
- Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.J Immunol. 2003; 170: 4069-4076
- Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling.Science. 2004; 305: 1153-1157
- Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.J Immunol. 2007; 178: 2721-2729
- Dysfunctional T regulatory cells in multiple myeloma.Blood. 2006; 107: 301-304
- Toll pathway-dependent blockade of CD4 + CD25 + T cell-mediated suppression by dendritic cells.Science. 2003; 299: 1033-1036
- In vivo peripheral expansion of naive CD4 + CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.Blood. 2006; 107: 3940-3949
- A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.Nat Med. 2007; 13: 139-145
- Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma.Eur J Intern Med. 2006; 17: 412-416
- Interleukin-21 is a growth and survival factor for human myeloma cells.Blood. 2002; 99: 3756-3762
- Myeloma proteins as tumor-specific transplantation antigens.Proc Natl Acad Sci U S A. 1972; 69: 1540-1544
- Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.Blood. 1995; 86: 3043-3049
- DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.Nat Med. 1998; 4: 1281-1286
- Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.Br J Haematol. 2003; 120: 27-35
- Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.Br J Haematol. 1996; 92: 840-846
- Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.Blood. 1998; 91: 2459-2466
- Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.Blood. 2003; 101: 4607-4610
- Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.Cancer Res. 2006; 66: 4496-4502
- Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.Blood. 1999; 94: 673-683
- Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.Leukemia. 2004; 18: 139-145
- Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.Bone Marrow Transplant. 2005; 36: 315-323
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.Int J Cancer. 1999; 83: 215-222
- Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.Br J Haematol. 2000; 108: 805-816
- Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.Biol Blood Marrow Transplant. 2000; 6: 621-627
- Optimizing dendritic cell-based immunotherapy in multiple myeloma.Br J Haematol. 2002; 117: 297-305
- Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study.Blood. 1999; 93: 2411-2419
- Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.Haematologica. 2003; 88: 1139-1149
- Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.Leuk Lymphoma. 2006; 47: 29-37
- Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.Cancer Res. 1999; 59: 3340-3345
- Migration of human dendritic cells after injection in patients with metastatic malignancies.Cancer Res. 1999; 59: 56-58
- Dendritic cells injected via different routes induce immunity in cancer patients.J Immunol. 2001; 166: 4254-4259
- Dendritic cells as the terminal stage of monocyte differentiation.J Immunol. 1998; 160: 4587-4595
- Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood. 2002; 99: 2512-2517
- Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.J Exp Med. 2007; 204: 831-840
- Heterogeneity of mucin gene expression in normal and neoplastic tissues.Cancer Res. 1993; 53: 641-651
- Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.Blood. 2000; 96: 3147-3153
- Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.J Immunol. 1994; 153: 2102-2109
- Cancer/testis-associated genes: identification, expression profile, and putative function.J Cell Physiol. 2003; 194: 272-288
Article info
Footnotes
The National Institutes of Health and Veterans Administration support this work.
Identification
Copyright
Published by Elsevier Inc.
